Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 114
- 试验地点
- 1
- 主要终点
- Incidence of chemotherapy-induced cardiotoxicity
研究概览
简要总结
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I
排除标准
- •Contraindication to ACE-inhibitors
- •On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
研究组 & 干预措施
enalapril arm
treatment with enalapril
干预措施: Enalapril (Drug)
结局指标
主要结局
Incidence of chemotherapy-induced cardiotoxicity
时间窗: 12 month period
次要结局
- Major adverse cardiac events, including death.(12 month period)